As such, ‘adjuvant’ hyperthermia and intraperitonealchemotherapy (HIPEC) could be a strategy to reduce the riskof PC and increase survival in stage II and III T4a patients.This clinical study aims to assess the burden of PC in T4tumors and the risk for local intraperitoneal recurrence as theonly site of metastatic disease. This is crucial to adequatelyestimate the potential benefits of HIPEC as an adjuvanttreatment strategy in T4 patients. Current literature on thisissue is scarce.